combination therapy

3:57
Bringing Dara into the first-line for multiple myeloma
Michael O’Dwyer
11:19
Immunotherapy for AML & ALL
Ivana Gojo et al.
1:24
Multiple myeloma treatment strategies: what does the future hold?
Enrique Ocio
2:24
Drug trial updates in multiple myeloma and SMM
Enrique Ocio
2:15
Waldenström’s macroglobulinemia: what options are available?
Jithma Abeykoon
1:45
Treating MM: the European strategy
Enrique Ocio
1:40
Rituximab combination therapy for waldenström’s macroglobulinemia
Jithma Abeykoon
1:21
Individualized therapy in waldenström’s macroglobulinemia
Jithma Abeykoon
2:04
Emerging therapies in AML: why patients should be optimistic
Naval Daver
1:43
PCNCL: what options are available?
Andrés Ferreri
1:17
First-line treatment of SAA: towards a new standard of care?
Regis Peffault de Latour
4:32
Improving outcomes in FLT3-mutated AML patients
Naval Daver
2:06
Venetoclax and ibrutinib for R/R CLL: analysis from the VIsion/HO141 trial
Arnon Kater
1:28
Venetoclax resistance in CLL
Arnon Kater
1:25
ANCHOR study updates
Enrique Ocio
3:23
Upcoming updates in multiple myeloma
Thierry Facon
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals